Transforaminal Epidural Injection in Acute Sciatica

Launched by C.L.A.VLEGGEERT-LANKAMP · Apr 18, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment option for patients suffering from sciatica, which is pain that travels down the leg and is often caused by issues with the spine. While most patients start with conservative treatments like rest and medication for the first 8 to 16 weeks, some may still experience significant pain that affects their daily activities. In this study, participants will be randomly assigned to either receive transforaminal epidural injections, which are injections aimed at reducing pain, or to continue with standard oral pain medications.

To be eligible for the trial, participants must be between the ages of 65 and 74, have a doctor’s diagnosis of sciatica, and report a pain level of 6 or higher on a scale of 1 to 10. They should have had symptoms for at least 3 weeks but no longer than 8 weeks. Participants can expect regular check-ins and assessments to monitor their pain and overall health during the trial. This study aims to find out if the injection can provide better pain relief than the usual medication, helping patients manage their discomfort while they wait to see if they need surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with sciatica by GP
• • NRS leg pain of 6 or more on a 10-point NRS scale
• • Minimum duration of symptoms of 3 weeks and maximum duration of 8 weeks
• Exclusion Criteria:
• • Age under 18 years
• • Condition preventing to receive transforaminal epidural injection
• • Severe scoliosis
• • Transforaminal epidural injection received in 6 months before randomization date
• • Surgery for sciatica at the same level
• • Surgery for sciatica at another level within one year before inclusion
• • Pregnancy